
Releases
Lakewood-Amedex to Showcase Nu-3 Antimicrobial at Investor Forum
Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics, will outline the firm's growth strategy and the progress of its lead candidate, Nu-3, during the Life Sciences Virtual Investor Forum on June 25. The presentation highlights the clinical-stage company's work on topical gels designed to treat infected diabetic foot ulcers.























